Long-term efficacy and safety of guselkumab in ulcerative colitis :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Guselkumab maintains remission in ulcerative colitis through 92 weeks

Ulcerative colitis Ulcerative colitis
Ulcerative colitis Ulcerative colitis

What's new?

Guselkumab maintains clinical remission in up to 74% of patients with ulcerative colitis through 92 weeks, with nearly all patients in remission remaining corticosteroid-free for at least 8 weeks.

Maintaining long-term remission while avoiding corticosteroid exposure is an important goal in ulcerative colitis (UC) management. Offering encouraging long-term evidence, the findings from the QUASAR long-term extension (LTE) study show that guselkumab (interleukin-23 inhibitor) sustains clinical remission through 92 weeks, with nearly all patients remaining corticosteroid-free for at least 8 weeks.

The study, led by Gary R. Lichtenstein et al., explored the long-term potency of guselkumab in patients with UC who responded to intravenous (IV) induction therapy. At maintenance week 0 (M-0), subjects were randomly allocated in a 1:1:1 ratio to get:

  • Subcutaneous guselkumab 100 mg every 8 weeks (q8w)
  • Subcutaneous guselkumab 200 mg every 4 weeks (q4w)
  • Placebo

Those completing the maintenance week 44 (M-44) visit could enter the LTE and continue their assigned intervention. Following unblinding after the M-44 analyses, placebo recipients discontinued treatment and were excluded from LTE efficacy analyses. Clinical remission at maintenance week 92 (M-92) was the key efficacy endpoint, while safety was assessed between M-44 and M-92.

Of 378 subjects randomly allocated to guselkumab at M-0, 329 (87%) entered the LTE. Among 303 subjects without maintenance dose adjustments (100 mg q8w, n = 155; 200 mg q4w, n = 148), 287 (95%) completed treatment through M-92.

Key results

  • Remission: At week M-92, clinical remission was sustained in both guselkumab dosing groups, with higher remission rates noted among those with available data than in the nonresponder imputation analysis (Table 1).

  • Corticosteroid-free remission: Of the 219 subjects in clinical remission at M-92, 218 (nearly 99.5%) had been corticosteroid-free for at least 8 weeks prior to assessment.
  • Safety: Findings from M-44 to M-92 were in line with the previously reported guselkumab's safety profile. 

Overall, guselkumab use yielded sustained clinical remission through 92 weeks in UC sufferers who respond to IV induction therapy. Both maintenance regimens exhibited durable efficacy, high treatment completion, and a consistent safety profile, with nearly all patients in remission remaining corticosteroid-free for at least 8 weeks.

Source:

American Journal of Gastroenterology

Article:

Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study

Authors:

Gary R. Lichtenstein et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: